Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Temporary Equity [Member] Legal Entity [Axis] Microbot Israel [Member] Related Party [Axis] Former Microbot Israel Shareholders [Member] Class of Stock [Axis] Series A Preferred Shares [Member] Alpha Capital [Member] Debt Instrument [Axis] Secured Note [Member] Convertible Note [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Merger Agreement [Member] Derivative Instrument [Axis] 2016 Series A and B Warrants [Member] Series A (2011) [Member] Series A (2013) [Member] Series A (2013) [Member] Series A (2015) [Member] Series A (2016) [Member] Series B (2016) [Member] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Israeli Innovation Authority [Member] Award Type [Axis] 2013 Through March 31, 2018 [Member] Technician Research And Development Foundation Limited [Member] Range [Axis] Minimum [Member] Maximum [Member] Title of Individual [Axis] Board of Directors [Member] Harel Gadot [Member] Income Tax Authority, Name [Axis] Israel Tax Authority [Member] Tax Period [Axis] From 2018 [Member] US Tax Authority [Member] Loan [Member] Exercise Price One [Member] Exercise Price Two [Member] Officer Lease Agreement [Member] Purchaser [Member] Preferred A Shares [Member] Securities Exchange Agreement [Member] Investor [Member] Securities Purchase Agreement [Member] Series A Convertible Preferred Stock [Member] Advisors [Member] Restricted Stock [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Warrant [Member] Hezi Himelfarb [Member] Exercise Price Three [Member] Car Lease Agreements [Member] Employees [Member] Employees and Consultant [Member] Currency [Axis] NIS [Member] Consultant [Member] Exercise Price Four [Member] Exercise Price Five [Member] CardioSert Ltd [Member] 2011 Series A Warrants [Member] Employees and Directors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Chief Technology Officer [Member] Plan Name [Axis] 2017 Equity Incentive Plan [Member] Preferred Stock [Member] Directors [Member] Research and Development Expense [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Other current assets Total current assets Fixed assets, net Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Trade payables Accrued liabilities Total current liabilities Derivative warrant liability Total liabilities Commitments and contingencies Temporary equity: Common stock of $0.01 par value; issued and outstanding: 10,702,838 shares as of March 31, 2018 and December 31, 2017 Shareholders' equity: Preferred stock of $0.01 par value; Authorized: 1,000,000 shares as of March 31, 2018 and December 31, 2017; issued and outstanding: 2,464 and 4,001 shares as of March 31, 2018 and December 31, 2017, respectively Common stock of $0.01 par value; Authorized: 220,000,000 as of March 31, 2018 and December 31, 2017; issued and outstanding: 31,417,589 and 29,880,289 shares as of March 31, 2018, and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total shareholders' equity Total liabilities and shareholders' equity Temporary equity, par value Temporary equity, shares issued Temporary equity, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development expenses, net General and administrative expenses Operating loss Financing income (expenses), net Net loss Net loss per share, basic and diluted Weighted-average number of common shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock Issuance of common stock, shares Share based compensation Share based compensation, shares Exercise of options Exercise of options, shares Cashless exercise of warrants Cashless exercise of warrants, shares Extinguishment of convertible notes and issuance of preferred A shares Extinguishment of convertible notes and issuance of preferred A shares, shares Conversion of preferred A shares to common stock Conversion of preferred A shares to common stock, shares Net loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Temporary equity Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Interest and revaluation of convertible notes, net Changes in fair value of derivative warrant liability Share-based compensation expense Changes in assets and liabilities: Other receivables Other payables and accrued liabilities Net cash used in operating activities INVESTMENT ACTIVITIES Purchase of property and equipment Net cash used in investing activities FINANCING ACTIVITIES Outflow in connection with current assets and liabilities acquired in reverse recapitalization, net Issuance of common stock, net of issuance costs Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents and restricted cash Cash and cash equivalents and restricted cash at the beginning of the period Cash and cash equivalents and restricted cash at the end of the period Supplemental disclosure of cash flow information: Non-cash financing transactions: Cashless exercise of warrants Conversion of preferred A shares into common shares Organization, Consolidation and Presentation of Financial Statements [Abstract] General Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Convertible Loan from Shareholders Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Warrant Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Share Capital Earnings Per Share [Abstract] Basic and Diluted Net Loss Per Share Income Tax Disclosure [Abstract] Taxes on Income Subsequent Events [Abstract] Subsequent Events Unaudited Interim Financial Statements Significant Accounting Policies Recent Accounting Standards Schedule of Outstanding Warrants Liabilities Schedule of Valuation of Derivative Warrant Liabilities Schedule of Fair Value Assumption Schedule of Liabilities Measured on a Recurring Basis Summary of Stock Option Activity Schedule of Stock Options Outstanding Schedule of Stock Options Valuation Assumptions Schedule of Basic and Diluted Net Loss Per Share Schedule of Deferred Tax Assets Schedule of Statutory Corporate Tax Rate and Effective Income Tax Rate Conversion value of shares Reverse stock split Conversion of stock number of common stock issued Conversion option to purchase common stock Restricted shares issued Cash and cash equivalent Loans receivable Loan bears interest rate Debt conversion, preferred shares issued Debt conversion, warrant issued Exercise price of warrants Proceeds from exercise of warrant The loan bears interest rate Debt, discount rate Common stock issued in connection with conversion of loan at the merger Secured note principal amount Principal and accrued interest of note Debt maturity date Convertible note, conversion price Warrants exercise price Common shares issued upon exercise of warrants Warrant outstanding Number of common stock issued in prior to the merger Cashless exercise warrants Warrant calculation description Volatility rate Risk free rate Number of Warrant Outstanding, shares Warrant Exercise Price, Per Share Warrant Exercisable Number of Warrant Exercisable, Period Estimated fair value of warrant liability Balances at December 31, 2017 Exercised Cancelled Changes in fair value Balances at March 31, 2018 Share price Exercise price Expected volatility Risk-free interest Dividend yield Expected life of up to (years) Beginning balance Revaluation of warrants Exercise warrants Ending balance Total grants obtained Royalties payable as percentage of future sales Lease term Monthly lease payment Compensation commitments Purchase price of Plaintiffs Loss contingency, damages sought Initial payment Investments Buy back amount per patent Monthly consultation fee Conversion of stock into shares Authorized capital stock Ordinary shares, par value Common stock, shares issued, including temporary equity Common stock, shares outstanding, including temporary equity Reverse stock splits Rights to acquire shares of common stock Designated preferred stock Number of common stock shares sold during the period Common stock price per share Proceeds from issuance of shares Placement agent fee Number of stock options granted Number of stock option granted as adjustment of reflect merger Weighted-average exercise price per share, granted Stock option merger retroactively adjusted exercise price per share Stock-based employee compensation Stock option vested term Number of option exercised Number of shares issued for services Number of shares issued for services, value Number of shares issued during period Common stock shares issued and outstanding reduced during the period Debt instrument face amount Loss on extinguishment of convertible note Repurchase of common stock Fair market value percentage Temporary equity value Number of Stock Options Outstanding, Outstanding at Beginning Balance Number of Stock Options Outstanding, Granted Number of Stock Options Outstanding, Exercised Number of Stock Options Outstanding, Cancelled Number of Stock Options Outstanding, Outstanding at Ending Balance Number of Stock Options Outstanding, Vested and expected-to-vest at end of period Weighted Average Exercise Price, Outstanding at Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, Outstanding at Ending Balance Weighted Average Exercise Price, Vested and expected-to-vest at end of period Aggregate intrinsic value, Stock Options Outstanding at Beginning period Aggregate intrinsic value, Stock Options Outstanding at End period Aggregate intrinsic value, Vested and expected-to-vest at end of period Exercise price Stock options outstanding Weighted average remaining contractual life Stock options exercisable Per share Expected volatility Risk-free interest Dividend yield Expected life of up to (years) Net loss attributable to shareholders of the company Net loss attributable to shareholders of preferred shares Net loss used in the calculation of basic net loss per share Net loss per share Weighted average number of common shares Corporate income tax rate Income tax reconciliation description Reduced federal tax rate Net operating losses carried forward Operating loss carryforwards, expiration Net operating loss carry-forward Total deferred tax assets Valuation allowance Net deferred tax asset Net loss as reported in the statements of operations Statutory tax rate Income Tax under statutory tax rate Change in valuation allowance Actual income tax Number of options to purchase common stock Advisors [Member] Alpha Capital [Member] Board of Directors [Member] Convertible Note [Member] Decrease [Member] Definitive Agreement [Member] Deposit in Escrow Account [Member] Designated preferred stock. Employees and Directors [Member] Escrow Account [Member] Exercise Price One [Member] Exercise Price Two [Member] Former Microbot Israel Shareholders [Member] Furniture And Office Equipment [Member] Increase [Member] Interested and Related Parties [Member] Israeli Innovation Authority [Member] June 2016 Agreements [Member] Loan [Member] MEDX Venture Group LLC [Member] Merger Agreement [Member] Microbot Israel [Member] Net Sales Royalty Percentage Office Lease Agreement [Member] Preferred A Shares Microbot Medical Ltd. Post-Merger [Member] Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member] Prior to Decmber 31, 2016 [Member] Prior to November 11, 2016 [Member] Research Equipment and Software [Member] Rights to acquire shares of common stock. Securities Exchange Agreement [Member] Series A (2011) [Member] Series A (2015) [Member] Series A (2016) [Member] Series A (2013) [Member] Series A (2013) One [Member] Series B (2016) [Member] Temporary Equity [Member] Three Israeli Shareholders [Member] From 2018 [Member] 2015 [Member] 2014 [Member] 2017 [Member] 2016 [Member] 2016 Series A Warrants [Member] Two Thousand Sixteen Series A and B Warrants [Member] US Tax Authority [Member] Warrant calculation description. Outflow in connection with current assets and liabilities acquired in reverse recapitalization, net. Accrued Interest [Member]. Series A Two Thousand And Eleven One [Member]. Cashless exercise warrants. Revaluation of warrants. Exercise warrants. Lease term. Research Agreement [Member]. Securities Purchase Agreement [Member] Compensation commitments. Purchaser [Member]. Fair market value percentage. Number of Warrant Exercisable, Period. Conversion value of shares. Common Stock Issued In Connection With Conversion Of Loan At Merger. Officer Lease Agreement [Member]. Number Of Stock Option Granted As Adjustment Of Reflect Merger. Net Loss Per Share Basic Diluted. Extinguishment of convertible notes and issuance of preferred shares. Extinguishment of convertible notes and issuance of preferred shares, shares. Preferred Stock [Member] Cashless exercise of warrants. Conversion of convertible notes into preferred A shares. Unamortized Discount [Member] Adjusted As Reserve Stock Split [Member] December 2016, And In May 2017 [Member] Consultant [Member] Series A Convertible Preferred Shares [Member] Stock Issued During Period Shares Cashless Exercise Of Warrants. Stock Issued During Period Value Cashless Exercise Of Warrants. Stock option merger retroactively adjusted exercise price per share. Common stock shares issued and outstanding reduced during the period. Warrant Exercisable. Employment Agreement [Member] General Manager and Chief Operating Officer [Member] Automobile Lease Agreement [Member] Hazel Gadot [Member] Hezi Himelfarb [Member] Exercise Price Three [Member] Number of common stock issued in prior to the merger. Derivative warrant liabilities. Exercised. Cancelled. Technician Research And Development Foundation Limited [Member] Employees [Member] Employees and Consultant [Member] Exercise Price Four [Member] Exercise Price Five [Member] Tax Act [Member] Operating Loss Carryforwards, Expiration. CardioSert Ltd [Member] Buy back amount per patent. NIS [Member] 2011 Series A Warrants [Member] From January 1, 2018 [Member] Unaudited Interim Financial Statements [Policy Text Block] Significant Accounting Policies [Policy Text Block] Directors [Member] Chief Technology Officer [Member] 2017 Equity Incentive Plan [Member] 2013 Through March 31, 2018 [Member] Series A Convertible Preferred Stock [Member] Car Lease Agreements [Member] Common stock, shares issued, including temporary equity. Common stock, shares outstanding, including temporary equity. SeriesATwoThousandAndThirteenOneMember Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Interest and Debt Expense Shares, Outstanding Interest on Convertible Debt, Net of Tax Increase (Decrease) in Other Receivables Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities OutflowInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CashlessExerciseOfWarrants DerivativeWarrantLiabilitiesBeginningBalance Gain (Loss) on Extinguishment of Debt Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance